Zentalis Pharmaceuticals Inc logo

ZNTL

Zentalis Pharmaceuticals Inc

$24.94

Earnings Summary

Revenue
$0Mn
Net Profits
$-59.08Mn
Net Profit Margins
-Inf%

Highlights

Revenue:

Zentalis Pharmaceuticals Inc’s revenue jumped NaN% since last year same period to $0Mn in the Q1 2022. On a quarterly growth basis, Zentalis Pharmaceuticals Inc has generated NaN% jump in its revenue since last 3-months.

Net Profits:

Zentalis Pharmaceuticals Inc’s net profit fell -18.39% since last year same period to $-59.08Mn in the Q1 2022. On a quarterly growth basis, Zentalis Pharmaceuticals Inc has generated -18.01% fall in its net profits since last 3-months.

Net Profit Margins:

Zentalis Pharmaceuticals Inc’s net profit margin jumped NaN% since last year same period to -Inf% in the Q1 2022. On a quarterly growth basis, Zentalis Pharmaceuticals Inc has generated NaN% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Zentalis Pharmaceuticals Inc post its latest quarter earnings

EPS Estimate Current Quarter
-1.19
EPS Estimate Current Year
-1.19

Highlights

EPS Estimate Current Quarter:

Zentalis Pharmaceuticals Inc’s earning per share (EPS) estimates for the current quarter stand at -1.19 - a 2.46% jump from last quarter’s estimates.

EPS Estimate Current Year:

Zentalis Pharmaceuticals Inc’s earning per share (EPS) estimates for the current year stand at -1.19.

Key Ratios

Key ratios of the Zentalis Pharmaceuticals Inc post its Q1 2022 earnings

Earning Per Share (EPS)
-1.31
Return on Assets (ROA)
-0.32
Return on Equity (ROE)
-0.48
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Zentalis Pharmaceuticals Inc’s earning per share (EPS) fell -5.65% since last year same period to -1.31 in the Q1 2022. This indicates that the Zentalis Pharmaceuticals Inc has generated -5.65% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Zentalis Pharmaceuticals Inc’s return on assets (ROA) stands at -0.32.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Zentalis Pharmaceuticals Inc’s return on equity (ROE) stands at -0.48.

Dividend Per Share (DPS):

Zentalis Pharmaceuticals Inc declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-05
-1.22
-1.31
-7.38%

Company Information

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company is developing a broad pipeline of potentially best-in-class oncology candidates, all internally discovered, which include ZN-c5, an oral selective estrogen receptor degrader (SERD) for ER+/HER2- breast cancer, ZN-c3, a WEE1 inhibitor for advanced solid tumors, ZN-d5, a BCL-2 inhibitor for hematologic malignancies, and ZN-e4, an EGFR inhibitor for non-small cell lung carcinoma (NSCLC). Zentalis has licensed ZN-c5, ZN-c3 and ZN-d5 to its majority-owned joint venture, Zentera Therapeutics, to develop and commercialize these candidates in China. Zentalis has operations in both New York and San Diego.

Organisation
Zentalis Pharmaceuticals Inc
Employees
124
Industry
Health Technology